132 related articles for article (PubMed ID: 37696296)
1. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
Deininger K; Raacke JN; Yousefzadeh-Nowshahr E; Kropf-Sanchen C; Muehling B; Beer M; Glatting G; Beer AJ; Thaiss W
Nuklearmedizin; 2023 Oct; 62(5):284-292. PubMed ID: 37696296
[TBL] [Abstract][Full Text] [Related]
2. Total metabolic tumor volume on
Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
[TBL] [Abstract][Full Text] [Related]
3. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
4. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
6. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
7. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
10. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
12. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of maximum standardized uptake value on
Qiu X; Liang H; Zhong W; Zhao J; Chen M; Zhu Z; Xu Y; Wang M
Thorac Cancer; 2021 Mar; 12(6):845-853. PubMed ID: 33512768
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
[TBL] [Abstract][Full Text] [Related]
18. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
[TBL] [Abstract][Full Text] [Related]
19.
Li Y; Wu X; Huang Y; Bian D; Jiang L
Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
